Vera Therapeutics, Inc.
corporate_fare Company Profile
Vera Therapeutics, Inc. (NASDAQ:VERA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for VERA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VERA spans 10-Q, 8-K, 144, DEF 14A.
Recent high-impact activity:
- Vera 10-Q: First TRUTAKNA Revenue $10.3M, Cash $384M, Q4 Charge of Up to $14.6M
- Vera Q3: First TRUTAKNA Revenue of $10.3M, Net Loss Narrows to $93.7M
- Vera Therapeutics Q3 Loss Narrower Than Expected at $93.7M
- TRUTAKNA Hits All Endpoints in ORIGIN 3 Final Analysis — 76% Risk Reduction in Kidney Disease Progression
- TRUTAKNA Cuts Kidney Disease Progression by 76% in Phase 3, Setting Stage for Full Approval
Financial Snapshot
Short Interest & Short Volume
8.47 days to coverFINRA reported short interest of 12,141,556 shares in VERA as of the October 30, 2026 settlement, a 10.6% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 63.9% of VERA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.